Change Language

Select Language

Global 3D Bioprinting Market to Reach US$ 2,260.1 Million by 2027, Bolstered by Technological Advancements

Published on Dec 20, 2021

The latest report by IMARC Group, titled “3D Bioprinting Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” finds that the global 3D bioprinting market reached a value of US$ 869 Million in 2021. 3D bioprinting refers to the medical application of 3D printers for fabricating biological tissues and organs through the layering of living cells. It creates spatially-controlled patterns in 3D where viability and cell function are conserved within the printed construct. 3D bioprinting utilizes a layer-by-layer method to deposit materials like bio-inks. Bio-inks are obtained from living cells, biomaterials, and active biomolecules to create the 3D structure of tissues and organs. The technology offers speedy and accurate drug testing as potential drug compounds can be tested on bio-printed tissue before being used in human trials. It is also used to build complex bodily structures, including bones, skin, vascular grafts, tracheal splints, heart tissues, and cartilages. As a result, 3D bioprinting finds applications in the research and development of drugs, scaffolds, and medical implants.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report. 

Global 3D Bioprinting Market Trends: 

The market is primarily driven by the increasing geriatric population and rising instances of respiratory and cardiovascular diseases that require organ transplants. The limited number of organ donors is propelling the demand for 3D bioprinting across healthcare organizations. In addition to this, the technology is used in cosmetic surgeries and the pharmaceutical industry, further supplementing the market growth. This has also resulted in growing public and private fundings, which have prompted market players to improve and strengthen their manufacturing and distribution capabilities. As a result, 3D bioprinting is used to create simple tissue structures in a lab setting; however, it can also build complete organs for transplants in the future, owing to technological advancements and the manufacturing of customized products. Moreover, manufacturers have introduced organ-on-a-chip and bio-printed structures that enable a 3D in-vitro analysis of bodily functions and aids in developing artificial organs and tissues. Furthermore, extensive R&D investments and increasing stem cell research have increased awareness regarding 3D bioprinting, which is positively influencing the market growth. Looking forward, the market value is expected to grow at US$ 2,260.1 Million by 2027, exhibiting a CAGR of 16.85% during the forecast period (2022-2027).

Market Summary: 

  • Based on the component, the market has been segmented into 3D bioprinters (syringe/extrusion, inkjet, magnetic levitation, laser-assisted, and other bioprinting), scaffolds, and biomaterials (living cells, hydrogels, extracellular matrices, and others).
  • On the basis of the application, the market has been classified into research (drug research, regenerative medicine, and 3D cell culture), and clinical (skin, bone and cartilage, blood vessels, and others).
  • The market has been categorized based on the end user into hospitals, research organization and academic institutes, and biopharmaceuticals companies.
  • Region-wise, the market has been divided into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
  • The competitive landscape of the market has been examined, with some of the key players being 3D Systems Inc., Aspect Biosystems Limited, Cellink AB, Cyfuse Biomedical K.K., EnvisionTEC GmbH (Desktop Metal Inc.), GeSiM – Gesellschaft für Silizium-Mikrosysteme mbH, Materialise NV, Organovo Holdings Inc., Poietis, regenHU Limited, and Stratasys Limited.


About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us

USA: +1-631-791-1145
Follow us on twitter : @imarcglobal


Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91-120-433-0800 )

Drop us an email at